Brahms AG
15
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
13.3%
2 terminated/withdrawn out of 15 trials
86.7%
+0.2% vs industry average
13%
2 trials in Phase 3/4
0%
0 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Risk Stratification Using Midregional Proadrenomedullin in the ED
Role: lead
Chromogranin A as Blood Marker in Cancer Patients
Role: lead
Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)
Role: collaborator
Identifying Patients With Suspicion of Infection in the ED Who Have Low Disease Severity Using MR-proADM - Pilot Study
Role: lead
Improve Management of Heart Failure With Procalcitonin
Role: lead
Impact of Therapy Optimization on the Level of Biomarkers in Patients With Decompensated Heart Failure
Role: collaborator
Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion
Role: collaborator
Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis
Role: collaborator
Procalcitonin Monitoring Sepsis Study
Role: lead
ICG- Liver Test Versus New Biomarkers as Prognostic Markers in Critically Ill Patients
Role: collaborator
Electrolyte and Fluid Disturbances in Subarachnoid Hemorrhage and Traumatic Brain Injury
Role: collaborator
Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection
Role: lead
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
Role: lead
Biomarkers in Acute Heart Failure
Role: lead
Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study
Role: collaborator
All 15 trials loaded